KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Tax Provisions (2019 - 2025)

Historic Tax Provisions for Aurinia Pharmaceuticals (AUPH) over the last 8 years, with Q3 2025 value amounting to $411000.0.

  • Aurinia Pharmaceuticals' Tax Provisions fell 1780.0% to $411000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 3072.08%. This contributed to the annual value of $1.7 million for FY2024, which is 18333.33% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Tax Provisions stood at $411000.0, which was down 1780.0% from $643000.0 recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Tax Provisions registered a high of $1.0 million during Q1 2025, and its lowest value of -$642000.0 during Q2 2023.
  • Over the past 5 years, Aurinia Pharmaceuticals' median Tax Provisions value was $436000.0 (recorded in 2023), while the average stood at $367368.4.
  • Its Tax Provisions has fluctuated over the past 5 years, first skyrocketed by 1182500.0% in 2022, then tumbled by 723333.33% in 2023.
  • Aurinia Pharmaceuticals' Tax Provisions (Quarter) stood at $726000.0 in 2021, then increased by 17.77% to $855000.0 in 2022, then crashed by 41.52% to $500000.0 in 2023, then crashed by 160.0% to -$300000.0 in 2024, then soared by 237.0% to $411000.0 in 2025.
  • Its last three reported values are $411000.0 in Q3 2025, $643000.0 for Q2 2025, and $1.0 million during Q1 2025.